149 related articles for article (PubMed ID: 37867335)
1. Metabolic Syndrome is Associated with Prostate Cancer Diagnosed on Biopsy but not the Gleason Score and the Number of Cancer-Positive Cores: A Prospective Controlled Study.
Bayraktar Z; Şahin C; Yıldırım S; Karaca Y; Sinanoğlu O
Arch Esp Urol; 2023 Sep; 76(7):504-510. PubMed ID: 37867335
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy.
De Nunzio C; Freedland SJ; Miano R; Trucchi A; Cantiani A; Carluccini A; Tubaro A
Prostate; 2011 Oct; 71(14):1492-8. PubMed ID: 21360562
[TBL] [Abstract][Full Text] [Related]
3. The metabolic syndrome is associated with more aggressive prostate cancer.
Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
[TBL] [Abstract][Full Text] [Related]
4. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
5. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E; Carrasco-Valiente J; Campos-Hernández JP; Blanca-Pedregosa AM; Jiménez-Vacas JM; Ruiz-García J; Valero-Rosa J; Luque RM; Requena-Tapia MJ
J Cell Mol Med; 2019 Feb; 23(2):934-942. PubMed ID: 30450757
[TBL] [Abstract][Full Text] [Related]
6. Association of metabolic syndrome with prostate cancer diagnosis and aggressiveness in patients undergoing transrectal prostate biopsy.
Fragkoulis C; Glykas I; Tzelves L; Stasinopoulos K; Lazarou L; Kaoukis A; Dellis A; Stathouros G; Papadopoulos G; Ntoumas K
Arch Ital Urol Androl; 2021 Sep; 93(3):291-295. PubMed ID: 34839634
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
9. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
Sourbeer KN; Howard LE; Andriole GL; Moreira DM; Castro-Santamaria R; Freedland SJ; Vidal AC
BJU Int; 2015 May; 115(5):736-43. PubMed ID: 24931061
[TBL] [Abstract][Full Text] [Related]
11. Patients with metabolic syndrome and widespread high grade prostatic intraepithelial neoplasia are at a higher risk factor of prostate cancer on re-biopsy: a prospective single cohort study.
Cicione A; Cantiello F; De Nunzio C; Tubaro A; Damiano R
Urol Oncol; 2014 Jan; 32(1):28.e27-31. PubMed ID: 23273912
[TBL] [Abstract][Full Text] [Related]
12. Association of Gleason score with PSA Values and Serum Testosterone Levels Measured Prior To Prostate Biopsy.
Temel MC; Ediz C; Akan S; Ozer E; Yilmaz O
J Coll Physicians Surg Pak; 2020 Apr; 30(4):399-402. PubMed ID: 32513360
[TBL] [Abstract][Full Text] [Related]
13. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study.
De Nunzio C; Albisinni S; Freedland SJ; Miano L; Cindolo L; Finazzi Agrò E; Autorino R; De Sio M; Schips L; Tubaro A
Urol Oncol; 2013 Oct; 31(7):997-1002. PubMed ID: 21925906
[TBL] [Abstract][Full Text] [Related]
14. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
15. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Transrectal Ultrasound Guided Biopsy Versus Transperineal Template Biopsy of the Prostate in Diagnosing Prostate Cancer in Men with Previous Negative Transrectal Ultrasound Guided Biopsy.
Nafie S; Wanis M; Khan M
Urol J; 2017 Mar; 14(2):3008-3012. PubMed ID: 28299763
[TBL] [Abstract][Full Text] [Related]
17. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.
Rais-Bahrami S; Siddiqui MM; Turkbey B; Stamatakis L; Logan J; Hoang AN; Walton-Diaz A; Vourganti S; Truong H; Kruecker J; Merino MJ; Wood BJ; Choyke PL; Pinto PA
J Urol; 2013 Nov; 190(5):1721-1727. PubMed ID: 23727310
[TBL] [Abstract][Full Text] [Related]
18. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
[TBL] [Abstract][Full Text] [Related]
19. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
